Novo Nordisk Net Income/Loss 2012-2026 | NVO
Novo Nordisk annual/quarterly net income/loss history and growth rate from 2012 to 2026. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Novo Nordisk net income/loss for the quarter ending March 31, 2026 was $7.604B, a 85.61% increase year-over-year.
- Novo Nordisk net income/loss for the twelve months ending March 31, 2026 was $43.390B, a 20.45% increase year-over-year.
- Novo Nordisk annual net income/loss for 2025 was $15.509B, a 5.91% increase from 2024.
- Novo Nordisk annual net income/loss for 2024 was $14.643B, a 20.51% increase from 2023.
- Novo Nordisk annual net income/loss for 2023 was $12.151B, a 54.54% increase from 2022.
|
Novo Nordisk Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2025 | $15,509 |
| 2024 | $14,643 |
| 2023 | $12,151 |
| 2022 | $7,862 |
| 2021 | $7,598 |
| 2020 | $6,456 |
| 2019 | $5,839 |
| 2018 | $5,906 |
| 2017 | $5,792 |
| 2016 | $5,636 |
| 2015 | $5,187 |
| 2014 | $4,722 |
| 2013 | $4,485 |
| 2012 | $3,703 |
| 2011 | $3,195 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $167.527B | $46.797B |
| Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |